CYP2C19 and osteoporosis: In addition to the above additive effects, all five PPIs described in this paper were found to competitively inhibit the activity of CYP2C19, decreasing liver enzyme activity and slowing the metabolic rate of drugs such as glucocorticoids in the body, which may further increase the risk of osteoporosis-related adverse events (Li et al., 2004).